arrow
H

Haiko J. Bloemendal

Radboud UMC
H指数:26
被引数:4,404

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Cancer Networks in the Netherlands: how do they affect quality and costs of care for colon or pancreatic cancer? A retrospective cohort study

荷兰综合癌症网络:它们如何影响结肠癌或胰腺癌患者的护理质量和费用?一项回顾性队列研究

2026-01-290
OA
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study

在PROMPT研究中,早期转移性去势抵抗性前列腺癌患者的分子反射测试

2025-10-310
OA
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer

治疗新转移性激素敏感性前列腺癌的难题

2025-04-110
OAAI
Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence

通过类似DRUG-Access Protocol (DAP)的平台解决临床价值的不确定性并改善新授权适应症的准入:真实世界证据的联合收集与评估

2024-09-010
PRE
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Cemiplimab在局部晚期或转移性皮肤鳞状细胞癌中的应用: 来自药物访问方案的前瞻性真实数据

2024-04-014
OA
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients

TP53功能丧失改变对转移性去势抵抗性前列腺癌患者对PSMA放射配体治疗的反应的影响

2024-01-010
OAAI
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs
2023-07-114
OAAI
Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

原发性结肠癌的共识分子亚型4 (CMS4) 靶向治疗: 一项概念验证研究

2022-09-0615
OAAI